Rgenix is a privately-held clinical-stage biopharmaceutical company developing first-in-class drugs that target key pathways in cancer progression.

310 E 67th St, Suite 1-12‎ New York, NY
(646) 856-9261

Ray Xie, PhD

Associate Director, Analytical & Pharmaceutical Sciences

Ray is responsible for the analytical development and related regulatory CMC filings of Inspirna’s drug candidates. Ray has over 15 years of experience in analytical development in the pharmaceutical industry. The majority of his career was with Celgene/Bristol Myers Squibb where Ray had increased responsibilities in various stages of drug development, from pre-INDs to new approvals (e.g. Pomalyst), to life cycle management (e.g., Pomalyst’s pediatric formulation). Ray was also a leading member of the Center of Excellence for Mass Spectrometry at Celgene, which provided innovative solutions to unknown impurity identification, elemental impurities and PGI quantitation for all drug candidates. Before joining Celgene, Ray worked on analytical development of late-stage drug candidates at Wyeth Pharmaceuticals, and that of marketed products at Johnson & Johnson.

Ray received his Ph.D. degree in Analytical Chemistry from Rutgers University in New Brunswick, New Jersey. He received his M.S degree in Physical Chemistry from Institute of Chemistry, Chinese Academy of Sciences in Beijing, China, and B.S degree in Chemistry from Tsinghua University in Beijing, China.